MARKET

PBYI

PBYI

Puma Biotechnology Inc
NASDAQ
5.29
+0.10
+1.93%
After Hours: 5.30 +0.01 +0.19% 17:47 12/04 EST
OPEN
5.16
PREV CLOSE
5.19
HIGH
5.32
LOW
5.16
VOLUME
421.35K
TURNOVER
--
52 WEEK HIGH
6.12
52 WEEK LOW
2.575
MARKET CAP
266.57M
P/E (TTM)
7.13
1D
5D
1M
3M
1Y
5Y
1D
PUMA BIOTECHNOLOGY REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 2d ago
Weekly Report: what happened at PBYI last week (1124-1128)?
Weekly Report · 3d ago
Weekly Report: what happened at PBYI last week (1117-1121)?
Weekly Report · 11/24 09:05
1stdibs.Com And 2 Other Penny Stocks To Watch Closely
Simply Wall St · 11/18 11:05
Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation
Reuters · 11/17 22:33
Weekly Report: what happened at PBYI last week (1110-1114)?
Weekly Report · 11/17 09:05
Director’s Bold Move: Major Stock Sale at Puma Biotechnology!
TipRanks · 11/14 02:13
Director Michael Patrick Miller Sells Common Shares of Puma Biotechnology Inc
Reuters · 11/13 21:41
More
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.

Webull offers Puma Biotechnology Inc stock information, including NASDAQ: PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.